Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials

Gao,Shan; Xie,Xingxing; Fan,Ling; Zhang,Deming

doi:10.3892/etm.2023.12214

Εfficacy and safety of vortioxetine (Lu AA21004) in the treatment of adult patients with major depressive disorder: A systematic review and a meta‑analysis of randomized controlled trials

Authors:
- Shan Gao
- Xingxing Xie
- Ling Fan
- Deming Zhang
View Affiliations

Affiliations: Department of Pharmacy, Chengdu Second People's Hospital, Chengdu, Sichuan 618000, P.R. China, Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China, Department of Pharmacy, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China, Department of Neurosurgery, Yaan People's Hospital, Yaan, Sichuan 625000, P.R. China
Published online on: September 20, 2023 https://doi.org/10.3892/etm.2023.12214
Article Number: 515
Copyright: © Gao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vortioxetine is a novel drug for the treatment of major depressive disorder (MDD). It has been reported that vortioxetine exhibits positive effect on the acute stage of MDD, while it can effectively prevent the recurrence of MDD during the maintenance period. Currently, the results of systematic reviews on vortioxetine are insufficient since several efficacy measures, such as the 24‑Items Hamilton Rating Scale for Depression (HADRS‑24) total score and other safety factors have not been evaluated. Therefore, the present study aimed to evaluate the efficacy and safety of different doses of vortioxetine on the treatment of adult patients with MDD via assessing more efficacy and safety indicators. The clinical, double‑blind, parallel and randomized controlled trials (RCTs) on the effect of vortioxetine on MDD were retrieved from PubMed\Medline, EBSCO, Embase, Cochrane Library, OVID, Web of Science and clinical trial registration websites from database inception to November 2022. A total of two investigators independently screened the included references and independently evaluated their quality. The meta‑analysis was performed using Revman 5.0 software. The present systematic review was registered in PROSPERO (registration no. CRD42018106343). In the present study 11 RCTs were included, with a total of 4,908 adult patients with MDD. More specifically, 1,158 patients were included in the 5‑mg vortioxetine group, 736 in the 10‑mg group, 298 in the 15‑mg group, 864 in the 20‑mg group and 1,852 in the placebo group. All 11 studies were randomized, double‑blinded and parallel control trials, and all publications were evaluated as high quality. The meta‑analysis results showed that patients in the 5‑, 10‑ and 20‑mg vortioxetine groups exhibited significantly higher Montgomery‑Asberg Depression Rating Scale (MADRS) response (≥50%) and remission (≤10%) rates compared with the placebo group (P<0.05). The pooled analysis also revealed a statistically significant change in the total score of HADRS‑24, MADRS, Sheehan Disability Scale (SDS), Clinical Global Impression Scale‑Improvement (CGI‑I) and HADRS‑24 response rate in the 10‑ and 20‑mg vortioxetine groups compared with the placebo group (P<0.05). However, no statistically significant changes in the total score of HADRS‑24, MADRS, SDS, CGI‑I and HADRS‑24 response rate were obtained in the 5‑mg group compared with the placebo group (P>0.05). Furthermore, the most common adverse events were nausea, hyperhidrosis, insomnia and vomiting, the incidence of which was increased with higher doses of vortioxetine. Overall, the results suggested that vortioxetine administration at doses of 5‑20 mg was significantly effective and safe compared with placebo in the treatment of MDD. However, 5 mg vortioxetine displayed no difference in the HADRS‑24, MADRS, SDS and CGI‑I total scores, and HADRS‑24 response rate. Furthermore, patient treatment with increasing vortioxetine doses was associated with good tolerance and high safety. Nevertheless, more multi‑center, high‑quality and long‑term RCTs are still needed to support the aforementioned findings.

View Figures

View References

1	Hirschfeld RM: Differential diagnosis of bipolar disorder and major depressive disorder. J Affect Disord. 169 (Suppl 1):S12–S16. 2014.PubMed/NCBI View Article : Google Scholar
2	DE Hert M, Correll CU, Bobes J, Cetkovich-Bakmas M, Cohen D, Asai I, Detraux J, Gautam S, Möller HJ, Ndetei DM, et al: Physical illness in patients with severe mental Disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 10:52–77. 2011.PubMed/NCBI View Article : Google Scholar
3	Grigoriadis S, VonderPorten EH, Mamisashvili L, Eady A, Tomlinson G, Dennis CL, Koren G, Steiner M, Mousmanis P, Cheung A, et al: The effect of prenatal antidepressant exposure on neonatal adaptation: A systematic review and meta-analysis. J Clin Psychiatry. 74:e309–e320. 2013.PubMed/NCBI View Article : Google Scholar
4	Hair P, Cameron F and Garnock-Jones KP: Levomilnacipran extended-release: First global approve. Drugs. 73:1639–1645. 2013.PubMed/NCBI View Article : Google Scholar
5	Sartorius N: Comorbidity of mental and physical disorders: A main challenge to medicine in the 21st century. Psychiatr Danub. 25 (Suppl 1):S4–S5. 2013.PubMed/NCBI
6	He S, Yang XM and Li HF: Levomilnacipran: A new drug for treatment of major depressive disorder. Chin J New Drugs Clin Rem. 34:418–422. 2015.PubMed/NCBI View Article : Google Scholar
7	Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A and Stensbøl TB: Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A novel multimodal compound for the treatment of major depressive disorder. J Med Chem. 54:3206–3221. 2011.PubMed/NCBI View Article : Google Scholar
8	Pehrson AL, Cremers T, Bétry C, van der Hart MG, Jørgensen L, Madsen M, Haddjeri N, Ebert B and Sanchez C: Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters a rat microdialysis and electrophysiology study. Eur Neuropsychopharmacol. 23:133–145. 2013.PubMed/NCBI View Article : Google Scholar
9	Gibb A and Deeks ED: Vortioxetine: First global approval. Drugs. 74:135–145. 2014.PubMed/NCBI View Article : Google Scholar
10	Boulenger JP, Loft H and Florea I: A randomized clinical study of Lu AA21004 in theprevention of relapse in patients with major depressive disorder. J Psychopharmacol. 26:1408–1416. 2012.PubMed/NCBI View Article : Google Scholar
11	FDA. Vortioxetine(EB/OL). http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/204447s000lbl.pdf, 2013-09-30.
12	Li G, Wang X and Ma D: Vortioxetine versus duloxetine in the treatment of patients with major depressive disorder: A Meta-analysis of randomized controlled trials. Clin Drug Investig. 36:509–517. 2016.PubMed/NCBI View Article : Google Scholar
13	Pae CU, Wang SM, Han C, Lee SJ, Patkar AA, Masand PS and Serretti A: Vortioxetine: A meta-analysis of 12 short-term, randomized, placebo-controlled clinical trials for the treatment of major depressive disorder. J Psychiatry Neurosci. 40:174–186. 2015.PubMed/NCBI View Article : Google Scholar
14	Baldwin DS, Chrones L, Florea I, Nielsen R, Nomikos GG, Palo W and Reines E: The safety and tolerability of vortioxetine: Analysis of data from randomized Placebo-controlledtrials and open-label extension studies. J Psychopharmacol. 30:242–252. 2016.PubMed/NCBI View Article : Google Scholar
15	Page MJ and Moher D: Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and Meta-analysis (PRISMA) statement and extensions: A scoping review. Syst Rev. 6(263)2017.PubMed/NCBI View Article : Google Scholar
16	Sandini M, Mattavelli I, Nespoli L, Uggeri F and Gianotti L: Systematic review and meta-analysis of sutures coated with triclosan for the prevention of surgical site infection after elective colorectal surgery according to the PRISMA statement. Medicine (Baltimore). 95(e4057)2016.PubMed/NCBI View Article : Google Scholar
17	Panic N, Leoncini E, de Belvis G, Ricciardi W and Boccia S: Evaluation of the endorsement of the preferred reporting items for systematic reviews and meta-analysis (PRISMA) statement on the quality of published systematic review and meta-analyses. PLoS One. 8(e83138)2013.PubMed/NCBI View Article : Google Scholar
18	Durak S, Ercan ES, Ardic UA, Yuce D, Ercan E and Ipci M: Effect of methylphenidate on neurocognitive test battery: An evaluation according to the diagnostic and statistical manual of mental disorders, fourth edition, subtypes. J Clin Psychopharmacol. 34:467–474. 2014.PubMed/NCBI View Article : Google Scholar
19	Shabsigh R and Rowland D: The Diagnostic and statistical manual of mental distal disorders, Fouth edition, text revision as an appropriate diagnostic for premature ejaculation. J Sex Med. 4:1468–1478. 2007.PubMed/NCBI View Article : Google Scholar
20	Faiad Y, Khoury B, Daouk S, Maj M, Keeley J, Gureje O and Reed G: Frequency of use of the international classification of diseases ICD-10 diagnostic categories for mental and behavioural disorders across world regions. Epidemiol Psychiatr Sci. 11:1–9. 2017.PubMed/NCBI View Article : Google Scholar
21	Janca A, Ustün TB, Early TS and Sartorius N: The ICD-10 symptom checklist: A companion to the ICD-10 classification of mental and behavioural disorders. Soc Psychiatry Psychiatr Epidemiol. 28:239–242. 1993.PubMed/NCBI View Article : Google Scholar
22	International Advisory Group for the Revision of ICD-10 Mental and Behavioural Disorders. A conceptual framework for the revision of the ICD-10 classification of mental and behavioural disorders. World Psychiatry. 10:86–92. 2011.PubMed/NCBI View Article : Google Scholar
23	Khan A, Lewis C and Lindenmayer JP: Use of non-parametric item response theory to develop a shortened version of the Positive and Negative Syndrome Scale (PANSS). BMC Psychiatry. 11(178)2011.PubMed/NCBI View Article : Google Scholar
24	Garcia-Caballero A, Torrens-Lluch M, Ramírez-Gendrau I, Garrido G, Vallès V and Aragay N: The efficacy of motivational intervention and cognitive-behavioral therapy for pathological gambling. Adicciones. 30:219–224. 2018.PubMed/NCBI View Article : Google Scholar : (In English, Spanish).
25	Health Quality Ontario. Psychotherapy for Major depressive disorder and generalized anxiety disorder: A health technology assessment. Ont Health Technol Assess Ser. 17:1–167. 2017.PubMed/NCBI
26	Hedges DW, Brown BL and Shwalb DA: A direct comparison of effect sizes from the clinical global impression-improvement scale to effect sizes from other rating scales in controlled trials of adult social anxiety disorder. Hum Psychopharmacol. 24:35–40. 2009.PubMed/NCBI View Article : Google Scholar
27	Higgins JPT and Green S, (eds.): Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. The Cochrane Collaboration, Available from: http://handbook.cochrane.org, (Updated March 2011).
28	Berhan A and Barker A: Vortioxetine in the treatment of adult patients with major depressive disorder: A meta-analysis of randomized double-blind controlled trials. BMC Psychiatry. 14:276–283. 2014.PubMed/NCBI View Article : Google Scholar
29	Braga VL, Rocha LPDS, Bernardo DD, Cruz CO and Riera R: What do Cochrane systematic reviews say about probiotics as preventive interventions? Sao Paulo Med J. 135:578–586. 2017.PubMed/NCBI View Article : Google Scholar
30	Henigsberg N, Mahableshwarkar AR, Jacobsen P, Chen Y and Thase ME: A randomized, double-blind, placebo-controlled 8-week trial of the efficacy and tolerability of multiple doses of Lu AA21004 in adults with major depressive disorder. J Clin Psychiatry. 73:953–959. 2012.PubMed/NCBI View Article : Google Scholar
31	Nishimura A, Aritomi Y, Sasai K, Kitagawa T and Mahableshwarkar AR: Randomized, double-blind, placebo-controlled 8-week trial of the efficacy, safety, and tolerability of 5, 10, and 20 mg/day vortioxetine in adults with major depressive disorder. Psychiatry Clin Neurosci. 72:64–72. 2018.PubMed/NCBI View Article : Google Scholar
32	Jain R, Mahableshwarkar AR, Jacobsen PL, Chen Y and Thase ME: A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder. Int J Neuropsychopharmacol. 16:313–321. 2013.PubMed/NCBI View Article : Google Scholar
33	McIntyre RS, Lophaven S and Olsen CK: A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. Int J Neuropsychopharmacol. 17:1557–1567. 2014.PubMed/NCBI View Article : Google Scholar
34	Mahableshwarkar AR, Jacobsen PL and Chen Y: A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder. Curr Med Res Opin. 29:217–226. 2013.PubMed/NCBI View Article : Google Scholar
35	Baldwin DS, Loft H and Dragheim M: A randomised, double-blind, placebo controlled duloxetine-referenced, fixed-dose study of three dosages of Lu AA21004 in acute treatment of major depressive disorder (MDD). Eur Neuropsychopharmacol. 22:482–491. 2012.PubMed/NCBI View Article : Google Scholar
36	Katona C, Hansen T and Olsen CK: A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. Int Clin Psychopharmacol. 27:215–223. 2012.PubMed/NCBI View Article : Google Scholar
37	Mahableshwarkar AR, Zajecka J, Jacobson W, Chen Y and Keefe RS: A randomized, placebo-controlled, active-reference, double-blind, flexible-dose study of efficacy of vortioxetine on cognitive function in major depressive disorder. Neuropsychopharmacology. 40:2025–2037. 2015.PubMed/NCBI View Article : Google Scholar
38	Boulenger JP, Loft H and Olsen CK: Efficacy and safety of vortioxetine (Lu AA21004), 15 and 20 mg/day: A randomized, double-blind, placebo-controlled, duloxetine-referenced study in the acute treatment of adult patients with major depressive disorder. Int Clin Psychopharmacol. 29:138–149. 2014.PubMed/NCBI View Article : Google Scholar
39	Mahableshwarkar AR, Jacobsen PL, Chen Y, Serenko M and Trivedi MH: A randomized, double-blind, duloxetine-referenced study comparing efficacy and tolerability of 2 fixed doses of vortioxetine in the acute treatment of adults with MDD. Psychopharmacology (Berl). 232:2061–2070. 2015.PubMed/NCBI View Article : Google Scholar
40	Alvarez E, Perez V, Dragheim M, Loft H and Artigas F: A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorder. Int J Neuropsychopharmacol. 15:589–600. 2012.PubMed/NCBI View Article : Google Scholar
41	Ma XR, Hou CL and Xia FJ: Present situation and challenges of somatic syndromes in patients with serious mental illness. Chin J Behav Med Brain Sci. 23:181–183. 2014.
42	Shen HN, Lu CL and Yang HH: Increased risks of acute organ dysfunction and mortality in intensive care unit patients with schizophrenia: A nationwide population-based study. Psychosom Med. 73:620–626. 2011.PubMed/NCBI View Article : Google Scholar
43	Lawrence D and Kisely D: Inequalities in healthcare provision for people with severe mental iuness. J Psychopharmacol. 24 (4 Suppl):S6l–S68. 2010.PubMed/NCBI View Article : Google Scholar
44	Ritchie S and Muldoon L: Cardiovascular preventive care for patients with serious mental illness. Can Fam Physician. 63:e483–e487. 2017.PubMed/NCBI
45	Kilbourne AM, Welsh D, McCarthy JF, Post EP and Blow FC: Quality of care for cardiovascular disease-related conditions in patients with and without mental disorders. J Gen Intern Med. 23:1628–1633. 2008.PubMed/NCBI View Article : Google Scholar
46	Zhao G, Ford ES, Dhingra S, Li C, Strine TW and Mokdad AH: Depression and anxiety among US adults: Associations with body mass index. Int J Obes (Lond). 33:257–266. 2009.PubMed/NCBI View Article : Google Scholar
47	Waller JA, Chen F and Sanchez C: Vortioxetine promotes maturation of dendritic spines in vitro: A comparative study in hippocampal cultures. Neuropharmacology. 103:143–154. 2016.PubMed/NCBI View Article : Google Scholar
48	Chen F, du Jardin KG, Waller JA, Sanchez C, Nyengaard JR and Wegener G: Vortioxetine promotes early changes in dendritic morphology compared to fluoxetine in rat hippocampus. Eur Neuropsychopharmacol. 26:234–245. 2016.PubMed/NCBI View Article : Google Scholar
49	Smagin GN, Song D, Budac DP, Waller JA, Li Y, Pehrson AL and Sánchez C: Histamine may contribute Tovortioxetine's procognitive effects; possibly through an orexigenic mechanism. Prog Neuropsychopharmacol Biol Psychiatry. 68:25–30. 2016.PubMed/NCBI View Article : Google Scholar
50	Meeker AS, Herink MC, Haxby DG and Hartung DM: The safety and efficacy of vortioxetine for acute treatment of major depressive disorder: A systematic review and meta-analysis. Syst Rev. 4(21)2015.PubMed/NCBI View Article : Google Scholar
51	Zhang X, Cai Y, Hu X, Lu CY, Nie X and Shi L: Systematic review and meta-analysis of vortioxetine for the treatment of major depressive disorder in adults. Front Psychiatry. 13(922648)2022.PubMed/NCBI View Article : Google Scholar
52	Thase ME, Mahableshwarkar AR, Dragheim M, Loft H and Vieta E: A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. Eur Neuropsychopharmacol. 26:979–993. 2016.PubMed/NCBI View Article : Google Scholar